Calcium zeolite hemostatic agent

Information

  • Patent Grant
  • 7595429
  • Patent Number
    7,595,429
  • Date Filed
    Monday, September 13, 2004
    20 years ago
  • Date Issued
    Tuesday, September 29, 2009
    15 years ago
Abstract
A composition for promoting the formation of clots in blood comprises a binder and a zeolite disposed in the binder, the zeolite having an adjusted calcium content. A method of forming a blood-clotting composition comprises the steps of providing a zeolite, combining the zeolite with a binder, and adjusting a calcium content of the zeolite to have an amount of calcium such that upon application of the composition to a wound, a heat of hydration is reduced and thereby heat transferred to the wound is reduced. A method of clotting blood flowing from a wound comprises the steps of applying a zeolite to the wound and maintaining the zeolite in contact with the wound for a predetermined amount of time. The zeolite preferably has an adjusted calcium content and is capable of producing a controllable blood clotting effect on the wound.
Description
TECHNICAL FIELD

The present invention relates to blood clotting devices (also referred to as hemostatic agents) and methods of controlling bleeding and, more particularly, to blood clotting materials and compositions and wound dressings for use as bleeding control devices.


BACKGROUND OF THE INVENTION

Blood is a liquid tissue that includes red cells, white cells, corpuscles, and platelets dispersed in a liquid phase. The liquid phase is plasma, which includes acids, lipids, solublized electrolytes, and proteins. The proteins are suspended in the liquid phase and can be separated out of the liquid phase by any of a variety of methods such as filtration, centrifugation, electrophoresis, and immunochemical techniques. One particular protein suspended in the liquid phase is fibrinogen. When bleeding occurs, the fibrinogen reacts with water and thrombin (an enzyme) to form fibrin, which is insoluble in blood and polymerizes to form clots.


In a wide variety of circumstances, animals, including humans, can be wounded. Often bleeding is associated with such wounds. In some instances, the wound and the bleeding are minor, and normal blood clotting functions in addition to the application of simple first aid are all that is required. Unfortunately, however, in other circumstances, substantial bleeding can occur. These situations usually require specialized equipment and materials as well as personnel trained to administer appropriate aid. If such aid is not readily available, excessive blood loss can occur. When bleeding is severe, sometimes the immediate availability of equipment and trained personnel is still insufficient to stanch the flow of blood in a timely manner.


Moreover, severe wounds can often be inflicted in very remote areas or in situations, such as on a battlefield, where adequate medical assistance is not immediately available. In these instances, it is important to stop bleeding, even in less severe wounds, long enough to allow the injured person or animal to receive medical attention.


In an effort to address the above-described problems, materials have been developed for controlling excessive bleeding in situations where conventional aid is unavailable or less than optimally effective. Although these materials have been shown to be somewhat successful, they are not effective enough for traumatic wounds and tend to be expensive. Furthermore, these materials are sometimes ineffective in all situations and can be difficult to apply as well as remove from a wound. Additionally, or alternatively, they can produce undesirable side effects.


Based on the foregoing, it is a general object of the present invention to provide a bleeding control device that overcomes or improves upon the prior art.


SUMMARY OF THE INVENTION

According to one aspect of the present invention, a composition for promoting the formation of clots in blood includes a binder and a zeolite disposed in the binder. The zeolite has an adjusted calcium content. A calcium content of the zeolite may be about 75 weight percent (wt. %) to about 83 wt. %. In another aspect of the present invention, a method of forming a blood-clotting composition includes the steps of providing a combination of a zeolite and a binder and adjusting a calcium content of the zeolite/binder combination with a calcium-containing compound such that upon application of the composition to a wound, a heat of hydration is reduced and thereby the heat transferred to tissue surrounding the wound is reduced. In yet a third aspect of the present invention, a method of clotting blood flowing from a wound includes applying a zeolite to the wound where bleeding is present and maintaining the zeolite in contact with the wound for a predetermined amount of time. Preferably, the zeolite has an adjusted calcium content and causes controllable blood clotting, thereby stopping or minimizing the flow of blood.


One advantage of the present invention is that it is easily applied to an open wound. Particularly when the composition is in paste, gel, or powder form, it can be readily removed from sterilized packaging and deposited directly at the points from which blood emanates to dress the wound. Alternately, the composition can be incorporated into a bandaging system and applied in conjunction with the bandaging system. By incorporating the composition into the bandaging system, the wound is treated and covered in a single step, thereby reducing the number of individual procedures required.


Another advantage of the present invention is that it rapidly and effectively promotes the clotting rate of blood. By causing blood to clot rapidly, a flow of blood can be reduced or stopped quickly.


Still another advantage is that the exothermic effects generally experienced upon application of a zeolite to blood are reduced. Because of the adjusted calcium content, a less-drastic temperature increase is realized when the zeolite contacts the blood emanating from a wound. Consequently, the discomfort experienced by a person or animal at the wound site will be minimized.







DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Disclosed herein are compositions and methods directed to the clotting of blood and the dressing of wounds. The compositions generally include molecular sieves in which a calcium content is adjusted. While the structures of the molecular sieves themselves serve to minimize or stop bleeding by absorbing at least portions of the liquid phases of blood, thereby promoting clotting, the calcium components thereof facilitate the dissipation of heats of hydration upon application of the sieves to the blood. The methods generally include the application of molecular sieves to bleeding wounds to provide dressings and removing components of the blood to facilitate the formation of clots while minimizing the heats of hydration generated.


In one embodiment of the present invention, a molecular sieve comprises a zeolite having an adjusted calcium content disposed in a binder. As used herein, the term “zeolite” refers to a crystalline form of aluminosilicate that may include several ionic species including sodium and calcium moieties. The preferred molecular structure of the zeolite is referred to as an “A-type” crystal. As used herein, the term “A-type crystal” is intended to indicate a crystal having a cubic structure and round holes. Suitable zeolites for use in the applications disclosed herein are also preferably nanoporous so as to provide increased surface areas. As used herein, the term “nanoporous” is intended to indicate an average pore diameter of about 3 angstroms to about 5 angstroms.


In another embodiment of the present invention, the zeolite comprises irregularly-shaped granular material that is prepared by grinding larger particles and then selecting material that will pass through a 16 mesh sieve screen but will not pass through a 40 mesh sieve screen. The resulting zeolite is a composition of irregular granules that range in size from 0.4 millimeters (mm) in diameter to 0.8 mm in diameter.


Zeolites for use in the disclosed applications may be naturally occurring or synthetically produced. Numerous varieties of naturally occurring zeolites are found as deposits in sedimentary environments as well as in other places and typically have about 90% calcium and about 10% sodium based on the total amount of calcium and sodium ions. Naturally occurring zeolites that may be applicable to the compositions and methods described herein include, but are not limited to, analcite, chabazite, heulandite, natrolite, stilbite, and thomosonite. Synthetically produced zeolites that may also find use in the compositions and methods described herein are generally produced by processes in which rare earth oxides are substituted by silicates, alumina, or alumina in combination with alkali or alkaline earth metal oxides.


The binder is preferably clay-based and may further include fillers (e.g., aluminum sulfate) or thickening agents that facilitate the selective application of the zeolite in various forms (e.g., as a paste, gel, powder, or erodable solid member). Natural clays that may provide suitable bases include, but are not limited to, kaolin, kaolinite, bentonite, montmorillonite, combinations of the foregoing clays, and the like. Modified clays such as polyorganosilicate graft polymers may also provide suitable bases.


The zeolite used for a blood clotting composition of the present invention includes an adjusted calcium content such that the calcium content is up to about 83 wt. % calcium and preferably about 75 wt. % to about 83 wt. % calcium. Adjustment of the calcium content of the zeolite provides a controlling factor in the efficacy of the blood clotting composition of the present invention. Increasing the calcium content to such a level substantially improves and enhances blood coagulation upon application of the blood clotting composition to blood. Furthermore, the exothermic effects that result from the application of the calcium zeolite to the blood are reduced.


To prepare the calcium zeolite for the present invention, the starting zeolite may be supplemented with a calcium-containing compound. Calcium-containing compounds that may be used to supplement the zeolite include, but are not limited to, calcium oxides, calcium sulfates, calcium chlorides, and the like, as well as combinations of any of the foregoing compounds.


Because of the presence of the calcium in the zeolite material in the amount as indicated above, the zeolite material generates less heat upon being fully saturated with water in the application of the zeolite to blood. In particular, heat generated by the application of the zeolite having up to about 83 wt. % calcium is inversely proportional to the total amount of calcium in the zeolite. A zeolite having about 80 wt. % calcium will generate less heat (when applied to blood) than the same zeolite not having supplemental calcium. Thus, when applied to a bleeding wound under conditions of actual use, the exothermic effects and heat transferred to the wound are reduced.


Upon treating wounds with the present invention, the remaining blood, which includes cells, corpuscles, platelets, and plasma, is concentrated. The platelets aggregate and interact with collagen, phospholipids, and lipid-containing proteins in the plasma. The aggregation of the platelets provide nuclei upon which fibrin binds to form a clot. Cells from the blood subsequently combine with the clot to form a mass. When blood emanates from a wound, the formation of the mass from the clot causes the flow of blood to cease, thereby eliminating further loss of blood. The blood pressure will often noticeably increase upon the application of the present invention due to cessation of blood loss.


Although this invention has been shown and described with respect to the detailed embodiments thereof, it will be understood by those of skill in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed in the above detailed description, but that the invention will include all embodiments falling within the scope of the appended claims.

Claims
  • 1. A composition for promoting the formation of clots in blood, said composition comprising: a binder; a zeolite disposed in said binder, said zeolite having an adjusted calcium content via the addition of a calcium-containing compound to said zeolite, said calcium content being between about 75 wt. % to about 83 wt. %, said composition being operable to reduce a heat of hydration when exposed to blood.
  • 2. The composition of claim 1, wherein said zeolite comprises aluminosilicate.
  • 3. The composition of claim 1, wherein said adjusted calcium content is obtained via the addition of a calcium-containing compound to a starting zeolite, said calcium-containing compound being selected from the group consisting of calcium oxides, calcium sulfates, and calcium chlorides.
  • 4. The composition of claim 1, wherein said zeolite is nanoporous.
  • 5. The composition of claim 1, wherein said binder is clay-based.
  • 6. The composition of claim 1, wherein said composition is of an irregularly-shaped granular form having a size distribution determined by sieving ground material with 40 mesh and 16 mesh cut-off screens.
  • 7. A method of forming a blood-cloning composition, said method comprising the steps of: providing a zeolite; combining said zeolite with a binder; and adjusting a calcium content of said zeolite via the addition of a calcium-containing compound to said zeolite, said calcium content being about 75 wt. % to about 83 wt. % and such that upon application of said composition to a wound, a heat of hydration is reduced and thereby heat transferred to said wound is reduced.
  • 8. The method of claim 7, wherein said adjusting said calcium content of said zeolite comprises supplementing said zeolite with a calcium-containing compound such that said calcium content is about 83 wt. %.
  • 9. A method of clotting blood flowing from a wound, said method comprising the steps of: providing a zeolite having a calcium content adjusted via the addition of a calcium-containing compound to said zeolite, said calcium content being about 75 wt. % to about 83 wt. %, and said zeolite being disposed in a clay binder;applying said zeolite to said wound, said zeolite being capable of producing a controllable blood clotting effect on said wound such that a heat of hydration is reduced; andmaintaining said zeolite in contact with said wound for an amount of time sufficient to cause blood flowing from said wound to clot.
CROSS REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/502,598 filed Sep. 12, 2003, entitled “Blood Clotting Compositions and Wound Dressings,” to Francis X. Hursey, the contents of which are incorporated herein by reference.

US Referenced Citations (79)
Number Name Date Kind
2688586 Eberl et al. Sep 1954 A
3122140 Crowe et al. Feb 1964 A
3181231 Breck May 1965 A
3366578 Michalko Jan 1968 A
3538508 Young Nov 1970 A
3723352 Alexander et al. Mar 1973 A
3979335 Golovko et al. Sep 1976 A
4373519 Errede et al. Feb 1983 A
4374044 Schaefer et al. Feb 1983 A
4379143 Sherry et al. Apr 1983 A
4525410 Hagiwara et al. Jun 1985 A
4626550 Hertzenberg Dec 1986 A
4631845 Samuel et al. Dec 1986 A
4748978 Kamp Jun 1988 A
4822349 Hursey et al. Apr 1989 A
4828081 Nordstrom et al. May 1989 A
4911898 Hagiwara et al. Mar 1990 A
4938958 Niira et al. Jul 1990 A
4956350 Mosbey Sep 1990 A
5140949 Chu et al. Aug 1992 A
5474545 Chikazawa Dec 1995 A
5486195 Myers et al. Jan 1996 A
5538500 Peterson Jul 1996 A
5556699 Niira et al. Sep 1996 A
5599578 Butland Feb 1997 A
5696101 Wu et al. Dec 1997 A
5716337 McCabe et al. Feb 1998 A
5725551 Myers et al. Mar 1998 A
5801116 Cottrell et al. Sep 1998 A
5826543 Raymond et al. Oct 1998 A
5941897 Meyers Aug 1999 A
5964239 Loux et al. Oct 1999 A
5981052 Sugiyama Nov 1999 A
6037280 Edwards et al. Mar 2000 A
6060461 Drake May 2000 A
6123925 Barry et al. Sep 2000 A
6159232 Nowakowski Dec 2000 A
6187347 Patterson et al. Feb 2001 B1
6203512 Farris et al. Mar 2001 B1
6372333 Sugiyama et al. Apr 2002 B1
6428800 Greenspan et al. Aug 2002 B2
6450537 Norris Sep 2002 B2
6475470 Kayane et al. Nov 2002 B1
6481134 Aledo Nov 2002 B1
6495367 Isogawa et al. Dec 2002 B1
6573419 Naimer Jun 2003 B2
6630140 Grunstein Oct 2003 B1
6745720 Rasner et al. Jun 2004 B2
6998510 Buckman et al. Feb 2006 B2
7371403 McCarthy et al. May 2008 B2
20020197302 Cochrum et al. Dec 2002 A1
20030133990 Hursey et al. Jul 2003 A1
20030176828 Buckman et al. Sep 2003 A1
20030199922 Buckman Oct 2003 A1
20030208150 Bruder et al. Nov 2003 A1
20040005350 Looney et al. Jan 2004 A1
20040166172 Rosati et al. Aug 2004 A1
20040243043 McCarthy et al. Dec 2004 A1
20050058721 Hursey Mar 2005 A1
20050070693 Hansen et al. Mar 2005 A1
20050074505 Hursey Apr 2005 A1
20050118230 Hill et al. Jun 2005 A1
20050137512 Campbell et al. Jun 2005 A1
20050143689 Ramsey, III Jun 2005 A1
20060078628 Koman et al. Apr 2006 A1
20060116635 Van Heugten Jun 2006 A1
20060141018 Cochrum et al. Jun 2006 A1
20060172000 Cullen et al. Aug 2006 A1
20060271094 Hudson et al. Nov 2006 A1
20070031515 Stucky et al. Feb 2007 A1
20070154509 Wilcher et al. Jul 2007 A1
20070154510 Wilcher et al. Jul 2007 A1
20070154564 Stucky et al. Jul 2007 A1
20070160638 Mentkow et al. Jul 2007 A1
20070275073 Huey et al. Nov 2007 A1
20080146984 Campbell et al. Jun 2008 A1
20080199539 Baker et al. Aug 2008 A1
20080299226 Mentkow et al. Dec 2008 A1
20080319476 Ward et al. Dec 2008 A1
Foreign Referenced Citations (30)
Number Date Country
1223208 Jun 1987 CA
0296324 Dec 1988 EP
0826822 Mar 1998 EP
0888783 Jul 1999 EP
1159972 May 2001 EP
1690553 Aug 2006 EP
1714642 Oct 2006 EP
1810697 Jul 2007 EP
2314842 Jan 1998 GB
61145120 Jul 1986 JP
2777279 Jul 1998 JP
11-332909 Jul 1999 JP
2004123651 Jul 2006 JP
WO 9505445 Feb 1995 WO
WO 9640285 Dec 1996 WO
WO 9913918 Mar 1999 WO
WO 0066086 Nov 2000 WO
WO 0182896 Aug 2001 WO
WO 0230479 Apr 2002 WO
WO 02060367 Aug 2002 WO
WO 02074325 Sep 2002 WO
WO 03074566 Sep 2003 WO
WO 2005012493 Feb 2005 WO
WO 2005027808 Mar 2005 WO
WO 2005087280 Sep 2005 WO
WO 2006012218 Feb 2006 WO
WO 2006088912 Aug 2006 WO
WO 2006102008 Sep 2006 WO
WO 2007120342 Oct 2007 WO
WO 2008036225 Mar 2008 WO
Related Publications (1)
Number Date Country
20050074505 A1 Apr 2005 US
Provisional Applications (1)
Number Date Country
60502598 Sep 2003 US